CoChat

Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer

Open access
de Geus-Oei, L.-F., van der Heijden, H. F.M., Visser, E. P., Hermsen, R., van Hoorn, B. A., Timmer-Bonte, J. N.H., Willemsen, A. T., Pruim, J., Corstens, F. H.M., Krabbe, P. F.M., Oyen, W. J.G. · 2007 · Journal of Nuclear Medicine
Cited by 121

The DOI matches its Crossref record.

Abstract

UNLABELLED: The aim of this prospective study was to evaluate the value of (18)F-FDG PET for the assessment of chemotherapy response in patients with non-small cell lung cancer. Furthermore, part of the objective of this study was to compare 2 methods to quantify changes in glucose metabolism. METHODS: In 51 patients, dynamic (18)F-FDG PET was performed before and at 5-8 wk into treatment. Simplified methods to measure glucose metabolism (standardized uptake value [SUV]) and quantitative measures (metabolic rate of glucose [MR(Glu)]), derived from Patlak analysis, were evaluated. The overall survival and progression-free survival with respect to MR(Glu) and SUV were calculated using Kaplan-Meier estimates. Fractional changes in tumor glucose use were stratified by the median value and also the predefined EORTC (European Organization for Research and Treatment of Cancer) metabolic response criteria, and criteria applying cutoff levels similar to those of RECIST (Response Evaluation Criteria in Solid Tumors) were evaluated. RESULTS: When stratifying at the median value of DeltaMR(Glu) and DeltaSUV, the difference in overall survival (P = 0.017 for DeltaMR(Glu), P = 0.018 for DeltaSUV) and progression-free survival (P = 0.002 for DeltaMR(Glu), P = 0.0009 for DeltaSUV) was highly significant. When applying the predefined criteria for metabolic response, the cutoff levels as also used for size measurement (RECIST) showed significant differences for DeltaSUV between response categories in progression-free survival (P = 0.0003) as well as overall survival (P = 0.027). CONCLUSION: The degree of chemotherapy-induced changes in tumor glucose metabolism as determined by (18)F-FDG PET is highly predictive for patient outcome, stratifying patients into groups with widely differing overall survival and progression-free survival probabilities. The use of (18)F-FDG PET for therapy monitoring seems clinically feasible, because simplified methods to measure tumor glucose use (SUV) are sufficiently reliable and can replace more complex, quantitative measures (MR(Glu)) in this patient population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2967/jnumed.107.043414

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 121

Metadata

Authors
de Geus-Oei, L.-F., van der Heijden, H. F. M., Visser, E. P., Hermsen, R., van Hoorn, B. A., Timmer-Bonte, J. N. H., Willemsen, A. T., Pruim, J., Corstens, F. H. M., Krabbe, P. F. M., & Oyen, W. J. G.
Venue
Journal of Nuclear Medicine
Published
2007-10-01
Volume
48
Issue
10
Pages
1592-1598
ISSN
0161-5505 (ISSN-L)
OpenAlex
W2096419883
Cited by
121
References
0
FWCI
9.37
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer. https://app.cochat.ai/papers/10.2967/jnumed.107.043414
The paper
de Geus-Oei, L.-F., van der Heijden, H. F. M., Visser, E. P., Hermsen, R., van Hoorn, B. A., Timmer-Bonte, J. N. H., Willemsen, A. T., Pruim, J., Corstens, F. H. M., Krabbe, P. F. M., & Oyen, W. J. G. (2007). Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.107.043414

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.